| Director Dealings Summary - Week Ended May 22 | ||||||||||||
| Company | Name | Position | Number of Shares | Resulting Holding | *Note | GBP Value | ||||||
| BUYS | ||||||||||||
| Topps Tiles | Matthew Williams | CEO | 1 million | 1.7 million | 1,270,000 | |||||||
| Countrywide | Alison Platt | CEO | 41,700 | 41,700 | Appointed CEO in September 2014. | 248,000 | ||||||
| Rank Group | Henry Birch | CEO | 100,000 | 100,000 | Same day as Rank said it expects full year results to meet management expectations. | 205,000 | ||||||
| Homeserve | John Gibson | Chairman | 40,000 | 115,000 | Day after reporting higher profit and said it would pay a special dividend of GBP97 million. | 172,000 | ||||||
| Sage Group | Jonathan Howell | Non-Executive Director | 18,167 | Undisclosed | 103,000 | |||||||
| AG Barr | Stuart Lorimer | CFO | 14,000 | 1.1 million | 87,000 | |||||||
| Homeserve | Ben Mingay | Non-Executive Director | 20,000 | 40,000 | Day after reporting higher profit and said it would pay a special dividend of GBP97 million. | 86,000 | ||||||
| Inspired Capital | Jeremy Coombes | Interim CEO | 535,000 | 2.9 million | 75,000 | |||||||
| Rank Group | Clive Jennings | CFO | 25,000 | 25,000 | Same day as Rank said it expects full year results to meet management expectations.. | 51,000 | ||||||
| STM Group | Michael Riddell | Chairman | 137,000 | Undisclosed | Week after STM said it made good start to 2015 and said trading so far this year is in line with its expectations. | 49,000 | ||||||
| Homeserve | Stella David | Non-Executive Director | 10,450 | 28,138 | 2 days after reporting higher profit and said it would pay a special dividend of GBP97 million. | 45,000 | ||||||
| Mitchells & Butlers | Eddie Irwin | Non-Executive Director | 10,000 | 30,000 | 45,000 | |||||||
| Amara Mining | John McGloin | Chairman | 271,249 | 1.6 million | 41,000 | |||||||
| McBride | Chris Smith | CFO | 25,657 | 25,657 | Appointed in January. | 24,000 | ||||||
| Oxford Biomedica | Tim Watts | CFO | 194,174 | 5.8 million | 19,000 | |||||||
| Symphony Environmental | Michael Stephen | Deputy Chairman | 151,000 | 933,998 | 15,000 | |||||||
| Symphony Environmental | Michael Laurier | CEO | 150,000 | 23 million | 14,000 | |||||||
| Verona Pharma | David Ebsworth | Chairman | 300,000 | 3.6 million | Week after Verona Pharma posted a widened pretax loss for 2014. | 11,000 | ||||||
| Lekoil | Greg Eckersley | Non-Executive Director | 50,000 | 2.8 million | Week after Lekoil said its pretax loss narrowed as administrative and finance costs fell. | 10,000 | ||||||
| Oxford Biomedica | Andrew Heath | Non-Executive Director | 100,000 | 1.1 million | 10,000 | |||||||
| Mortgage Advice Bureau | Lucy Tilley | CFO | 4,500 | 4,500 | Appointed in March. Was previously a director in Canaccord Genuity's corporate broking team, which worked on company's AIM listing. | 9,900 | ||||||
| Airea | Roger Salt | CFO | 58,738 | 228,738 | 9,000 | |||||||
| Symphony Environmental | Ian Bristow | CFO | 100,000 | 1.2 million | 9,000 | |||||||
| K3 Business Technology | Brian Davies | CFO | 2,253 | 9,537 | Bought shares from CEO David Bolton | 5,600 | ||||||
| Verona Pharma | Biresh Roy | CFO | 150,000 | 900,000 | Week after Verona Pharma posted a widened pretax loss for 2014. | 5,000 | ||||||
| Symphony Environmental | Nirj Deva | Chairman | 50,000 | 363,925 | 4800 | |||||||
| Verona Pharma | Jan-Anders Karlsson | CEO | 135,000 | 2.9 million | Week after Verona Pharma posted a widened pretax loss for 2014. | 4,700 | ||||||
| Symphony Environmental | Nicholas Clavel | Non-Executive Director | 50,000 | 550,000 | 4,500 | |||||||
| SELLS | ||||||||||||
| Glencore | William Macaulay | Non-Executive Director | 28 million | 42 million | Sold by FR Galaxy Holdings, an investment vehicle connected to Macaulay. | 84,000,000 | ||||||
| Moneysupermarket | Simon Nixon | Founder & non-executive deputy chairman | 20 million | 69.8 million | The amount of shares sold is at the top end of the range. Credit Suisse, the sole bookrunner on the placing, said it would sell a stake of between 2.8% and 3.7% on behalf of Nixon, who retains a 12.8% holding. | 56,000,000 | ||||||
| Merlin Entertainments | Nick Mackenzie | Manager | 440,000 | 1.5 million | Same day as Merlin reported growth in revenue boosted by new site openings, features and good weather, as it continues strategic expansion plans. | 2,000,000 | ||||||
| Countrywide | Grenville Turner | Chairman | 300,000 | 171,524 | 1,800,000 | |||||||
| Hays | Paul Venables | CFO | 750,000 | 953,014 | 1,200,000 | |||||||
| Sthree | Justin Hughes | Corporate Executive Officer | 267,500 | 390,867 | Has sold parcels of shares in quick succession since May 12. | 1,000,000 | ||||||
| Euromoney | Peter Ensor | Chairman | 20,421 | 175,918 | Same day as interim ex-dividend date. | 245,000 | ||||||
| Bloomsbury Publishing | Nigel Newton | CEO | 132,651 | 1.1 million | Day after Bloomsbury posted a small rise in pretax profit and said trading in its current year has been good across all of its divisions. | 232,000 | ||||||
| ITV | David Osborn | HR Director | 35,900 | Nil | 97,000 | |||||||
| Rolls-Royce | Jason Smith | Divisional CEO | 2,850 | 19,582 | 29,000 | |||||||
| K3 Business Technology | David Bolton | CEO | 2,253 | 994,961 | Sold shares to CFO Brian Davies. | |||||||
| *Note: A recent company event around the time of the dealing does not suggest the dealing took place because of that event. | ||||||||||||
| When a spouse or related party to a director buys shares, the resulting holding is the beneficial holding of the director | ||||||||||||
| Contact: +44 207 199 0340; newsroom@alliancenews.com; @AllNewsTeam | ||||||||||||
| Copyright 2015 Alliance News Limited. All Rights Reserved. | ||||||||||||
13 Jan 2020 11:08
Verona Pharma shares surge after results from latest study
(Sharecast News) - Respiratory disease-focussed biopharmaceuticals company Verona Pharma announced positive top-line data from a four week, 416 patient phase 2b dose-ranging study evaluating nebulised ensifentrine or placebo as an add-on treatment to 'Spiriva Respimat', or tiotropium, which is a long acting anti-muscarinic bronchodilator, in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD).
Read more